Navigation Links
Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
Date:2/11/2009

SAN CARLOS, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year ended December 31, 2008 on Wednesday, February 25, 2009, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com.

    To access the conference call, follow these instructions:
    Dial: 800.561.2718 (U.S.); 617.614.3525 (international)
    Participant Passcode: 32041145 (Howard Robin is the host)

An audio replay will also be available shortly after the call and will remain so through March 4, 2009.

    To access the replay, follow these instructions:
    Dial: 888-286-8010 (U.S.); 617-801-6888 (international)
    Participant Passcode: 44161634

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies. Nektar is also developing
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... York, NY (PRWEB) June 18, 2013 ... innovation and sustainability, the Consulate General of Switzerland in ... solar boat, Switzerland’s MS Tûranor PlanetSolar , to ... part of its DeepWater Expedition 2013 tour with scientists ... led by Capitain Gérard d’Aboville, runs exclusively on energy ...
(Date:6/18/2013)... 2013 DuPont welcomes 48 of the ... DuPont National AgriScience Teachers Ambassador Academy this week (NATAA) ... Md. , The NATAA “Ag Academy” is ... a special project of the National FFA Foundation ... (NAAE) . The highly recommended agriscience teachers, who ...
(Date:6/18/2013)... June 18, 2013 ... research firm, announces the initiation of full ... biopharmaceutical company developing and marketing products for ...      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) ... examining the investment merits of BioAlliance Pharma, ...
(Date:6/18/2013)... This webinar will examine the ... promotion, and review the basic FDA regulations and ... apply these principles through real world case studies ... fundamentals on FDA regulations and guidance related to ...     Assessing traditional and newer forms of promotional materials ...
Breaking Biology Technology:Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4DuPont Sponsors National AgriScience Ambassador Academy 2DuPont Sponsors National AgriScience Ambassador Academy 3Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2
... Sept. 18 /PRNewswire-FirstCall/-- Biodel Inc. (Nasdaq:,BIOD) today ... program,at the 43rd Scientific Sessions of the ... VIAject(TM) Phase II meal study data ... entitled, "Pharmacokinetics and pharmacodynamics of,insulin VIAject(TM), insulin ...
... Advantage of ... after HIV Infection, RICHMOND, Calif., Sept. 18 /PRNewswire-FirstCall/ ... the presentation of data,demonstrating that human CD4 T-cells can ... zinc finger DNA-binding protein nucleases,(ZFN(TM)) and preferentially survive and ...
... the Increasing Global Need for Genzyme Products, CAMBRIDGE, ... today broke ground on a significant expansion of its,flagship ... project is focused on adding space for manufacturing support,functions, ... The expansion was marked by a ceremony featuring ...
Cached Biology Technology:Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 3Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 2Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 3Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 4Sangamo BioSciences Presents Data Demonstrating 'In Vivo' Protection Against HIV Infection by CCR5-ZFN Therapeutic 5Genzyme Begins Major Expansion of Boston Manufacturing Facility 2Genzyme Begins Major Expansion of Boston Manufacturing Facility 3Genzyme Begins Major Expansion of Boston Manufacturing Facility 4Genzyme Begins Major Expansion of Boston Manufacturing Facility 5
(Date:6/18/2013)... of DNA and this modification can occur in ... now, scientists believed that this epigenetic phenomenon actively ... team of researchers from the University of Geneva ... at the Faculty of Medicine, reveals that this ... methylation may play both a passive and active ...
(Date:6/18/2013)... of Adelaide shows that weight gain and increased head size ... a higher IQ at early school age. , The study was ... from more than 13,800 children who were born full-term. , The ... that babies who put on 40% of their birthweight in the ... time they were six years of age, compared with babies who ...
(Date:6/17/2013)... with central nervous system infections may well be suffering ... to a study to be published in mBio ... for Microbiology. Researchers have detected the virus in spinal ... nervous system infections of unknown cause, and in an ... and poultry, suggesting animals may serve as reservoirs for ...
Breaking Biology News(10 mins):The secret of DNA methylation 2IQ link to baby's weight gain in first month 2New virus discovered in patients with central nervous system infections 2New virus discovered in patients with central nervous system infections 3
... more than 10 years of cooperative research on ... the USDA Forest Service,s Pacific Southwest Research Station ... Phytophthora ramorum : A Summary of the Literature." ... of topics, including a history of sudden oak ...
... Vegas, NV (Dec. 24, 2010) - Three weeks of ... heart attack returned microRNA activity close to their pre-event ... studied, just six were attributed to exerting the majority ... study four microRNA optimally regulated by Longevinex and ...
... An expert working group of the International ... Clinical Chemistry and Laboratory Medicine (IFCC) has released ... of bone turnover markers (BTMs) in fracture risk ... it identifies research priorities and recommends that specific ...
Cached Biology News:Comprehensive report on sudden oak death 2Longevinex exerts greater influence over genes than resveratrol 2Longevinex exerts greater influence over genes than resveratrol 3Standardized protocols would greatly enhance clinical and research potential of BTMs 2
When added to either StemSep CD4+ or CD8+ T Cell Enrichment cocktails, human CD69 TAC is designed to deplete human CD69 from samples to isolate resting CD4+ or CD8+ T cells....
This bispecific antibody complex has been tested for efficient depletion of CD41+ cells using the StemSep ; negative immunomagnetic cell separation system....
... is a modular confocal system that gives ... ultra-compact and lightweight design. The improved scan ... performance to 400nm andits bi-directional scanner provides ... X and Y scan axes rotation and ...
... COOLSCOPE is an integrated digital microscope ... a computer, equipment setup, optical adjustment or ... and innovative technology, COOLSCOPE combines simplicity and ... The COOLSCOPE offers simultaneous viewing of a ...
Biology Products: